focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
If they intended to sell early next week they wouldn’t have declared yet. Lots of investor relations next week and I suspect news will travel well over this weekend too. Good week ahead hopefully.
Quite right tucky.they have sold 11;543,612 . hopefully they' re now where they want to be for the time being and the s/p will be able to rise without their selling pressure.
Lombard haven’t just reduced to make way for the warrants. The TR-1 shows they’ve sold the warrants plus a bit more. If you work out what they hold now versus the new total shares to be in circulation it adds up.
I might be wrong but that’s what numbers I work out.
Sorry if this has already been mentioned but sales on Amazon UK have increased....now updated to show 2k+ units sold in the last week.
Hopefully, if current trends continue, looks as if the 50p resistance level broken. Next resistance level 60p. This coming Thursday's Investor Seminar and the following Mondays Retailers Meeting could well push it over the 60p onwards and upwards.
SP up probably because the mms know they have stopped selling. Space to convert the 9.375m warrants remaining without going over 29%. So onwards and upwards
Paid.
Bodes well for Monday open.
Speakin of lombard, TR1 in, their holding down, and the sp goes up!
Seems to be a bit of activity on Wall street open again. Potentially promising!
This is a problem of FUM's own making. They should have switched the name from Eroxon after P3 failure. When you google Eroxon, a large proportion of the answers refer to MED2005 rather than MED 3000. I did suggest 'Boneron' and 'Gotwood' at the time, but did they listen?
Jet7 - Agree with your synopses.
This situation is a little akin to internet startups who do really well to launch a platform and then the baton is passed on to a large established giant to develop it and generate huge profits. (A giant who makes and offer too good to refuse)
Thanks Chizzy. That is interesting. Interesting partly because it is wrong. I have seen a few articles now perpetuating the wrong idea that Eroxon contains GTN. A lot of this article focusses on GTN, which is just not an ingredient in Eroxon. There has been some lazy journalism around this. Proably not important in the bigger scheme of things but expected better from Forbes. It misses the important point about how Eroxon developed out of earlier products. Med2005 contained GTN and what we now have in Eroxon was the 'placebo' in a trial of Med2005, and performed just as well. GTN has side effects , including headaches, nausea etc, and Eroxon does not . Good that Eroxon is getting a lot of publicity, but people need accurate information about what it actually is......
Thanks Chizzy. That is interesting. Interesting partly because it is wrong. I have seen a few articles now perpetuating the wrong idea that Eroxon contains GTN. A lot of this article focusses on GTN, which is just not an ingredient in Eroxon. There has been some lazy journalism around this. Proably not important in the bigger scheme of things but expected better from Forbes. It misses the important point about how Eroxon developed out of earlier products. Med2005 contained GTN and what we now have in Eroxon was the 'placebo' in a trial of Med2005, and performed just as well. GTN has side effects , including headaches, nausea etc, and Eroxon does not . Good that Eroxon is getting a lot of publicity, but people need accurate information about what it actually is......
For me Lombard is a double edged sword, rightfully looking after both themselves and their investors. They have supported FUM over the years , its been very profitable for them and now they have I’d suggest, a golden nugget in their portfolio , that being Eroxon.
Make no mistake about it , I’m sure Lombard will be having a big say going forward and probably consulted on most important decisions to be taken. That in my view would be extremely beneficial for the prospects of Futura. Also Barder & Co have not gone through all that is past to reach this Eureka moment to screw it up now.
They now have what I describe as a wonder product on their hands for ED, the ball lies firmly in FUM’s court, plus being very well funded, owning 100% of the product, Lombard in the background offering all the knowledge and experience that they hold. This will take off at some point and all our dreams will come to the fore.
Bring on further good news JB!
I think the skills needed to build production plants is very different to what the BOD have now. They are the innovators .. I can’t see them building their own when it can get outsourced.
Worry is that this could be a case of not investing in the mine but the people making the pick axes.
Lombard.and BOD will have their own view of an exit… If they build the right team around them to commercialise this properly steady and strong income would pay them well - Barder’s divs would be very handsome right?? But if Lombard have a 3 year exit plan from the latest buyin they’d push for a sale right??
Buy showing great sales and disti contracts it then becomes valuable to a critically integrated pharma who can manufacture themselves so worth a significant premium??
"....but the main thing we need is coverage and big sales....." I would add production lines to support that.
Multinational Pharma's are set up to do just that.
81Lucky
Bardar & CO won't be out of there depth! in terms of taking this forward as it will be dealt with by partners, & you don't get to the stage they have by being out of your depth. Yes their not marketers or distributors, Being a Lab is their speciality. In their position you leave the Marketing & Distribution to the people your paying! The marketers & distributors already sell into these channels, It really is just another product for them. Only difference being a really exciting product with a colossal offering & opportunity for all concerned, so focus will be geared on this. When products like this are scaled out, it's about having good partner involvement, making sure that each involved is all doing what they signed up for. Provided everybody pulls there weight, then this will be a walk in the park. IMO having worked on a global product, it's protecting what you setup is prime. Making sure that the distributor network put in place is solid. That pricing is kept at a certain level. I'm not to ofay with medical market, but what you don't want are companies licenced to sell, doing so at lower pricing levels, although I'm sure pricing structures will have already been agreed a long time ago, & agreements put in place to prevent this happening. Key thing to remember is for all partners involved it is just another product for them. What really needs to happen is that your local GP's need to get behind the product to advise individuals that are brave enough to go to their GP & Pharmacies, are on top of their game with advice. Obviously that all online content which is where main business will generate is hitting the right audience. Women talk, they will be a large promoter of Eroxon, once their husbands have used & hopefully had success. I truly believe everything about this whole business & the way its moving forward is all positive & will turn out to be a real success story. In a report I read Viagra works for 77% of men so the figures are not much different, with this data being just with regards the ED market, when we know for both viagra & eroxon the market audience is much bigger, especially with eroxons main selling features. This investment I feel offers the best potential, most exciting potential that I have across my investments & I'm glad I stuck with it to this point. There's still a bit of a slow burn to go, maybe that's just felt because we are all a little impatient really when it comes to investments, but I think in 18mths time, we may all be smiling that little bit more! have a great Friday peeps!
They’ve outsourced everything pretty much. Which is a sensible way of doing it, the margins are lower but exponentially they can supply massive demand, same will be in America. The disti runs the promo campaign (which means they are going to get a large cut of the £25) but the main thing we need is coverage and big sales. The bigger the sales pipeline the better leverage with the producers. Classic thing in brewing is that a big co comes and buys a chunk to help with distribution and then ultimately buys the whole thing (Bevertown/lagunitas) but really we have distributors signed up right? All the BOD need to do is get the right commercial deals with the best distributors.
Strong UK and EU sales will ultimately help FUM land a nationwide disti in the US. Who no doubt will have connections in contract production.
I think the hockey stick 10 bagger we were hoping for isn’t gonna come. But I’ll agree with other comments on here that a steady influx of national disti agreements and sales data will keep this ticking upwards for quite a while.
GLA
Well. Amazon have told me my order has arrived. Out atm. Am I in the 60% or the outcasts. Will get back. Don’t think will work, cos pretty for gone.
That is why the commercialisation deals they've put in place, marketing/distribution etc are done by the companies. All FUM do is supply the product. But guessing management will give approval of any plans the comanpies suggest.
Chizzy - Soon Bardar and Co are going to be out of their depth. I totally agree with Missy-king post. What this will require is vertical marketing and distribution. (Assuming the patient aspect is airtight). All the planets are aligned for this to be taken to another level.
IMO I can't see that they will get brought out, as cash runway is good, marketing partners/ supply chains are underway/ in place with their chosen partners & no doubt US will be another large known distributor & key player in the US market. Yes if they were struggling with the outlay & experience as a LAB reaching out to these key players, then yes I might think it could be on the agenda. However I think they seem to have it in-hand, marketing a product such as this is very easy in the sense its been proven to be efficient in up to 66% of patient trials, its considered very safe with no side affects, it has a 150M ED market, & to add to their attributes its now FDA approved for the US. Word with a product like this spreads very easy! I can't see that another player needs to get involved. All that will be concentrated on now is the supply chain cogs, keeping them oiled & letting the distributors get it to the user. I think over the coming 18 months with all the news on new territories coming onboard we will see the SP bounce on news, & in-between inline with sales after first revenue financials published, we will see the SP steadily rising with the odd big spikes. That's my thoughts having worked on a product with similar scale out. I can't stop dreaming at the moment :)
I am absolutely convinced that this will end-up with a 'large outfit' (possibly a venture capitalist, even). I came across this article some time ago and was one of the reasons I stuck it out this long. I just can not get my head around the possibilities , if a large pharma got behind this product.
https://www.vice.com/en/article/538wka/how-big-pharma-makes-you-think-you-have-sex-problems
GSK itself wouldn't buy FUM. HALEON their consumer spin off might but begs the question does EROXON fit in their product portfolio (ie do they have a sexual interest). I'd probably think it could be RECKITT B that it might be more likely.